Hologic, Inc. (HOLX) Stake Lifted by WINTON GROUP Ltd
WINTON GROUP Ltd lifted its position in Hologic, Inc. (NASDAQ:HOLX) by 528.2% during the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 39,730 shares of the medical equipment provider’s stock after purchasing an additional 33,406 shares during the period. WINTON GROUP Ltd’s holdings in Hologic were worth $1,803,000 as of its most recent SEC filing.
Other institutional investors have also recently modified their holdings of the company. Commonwealth Bank of Australia grew its holdings in shares of Hologic by 31.0% in the second quarter. Commonwealth Bank of Australia now owns 2,533 shares of the medical equipment provider’s stock worth $114,000 after purchasing an additional 600 shares during the last quarter. National Asset Management Inc. bought a new position in shares of Hologic in the second quarter worth approximately $203,000. Beck Mack & Oliver LLC bought a new position in shares of Hologic in the second quarter worth approximately $209,000. Notis McConarty Edward bought a new position in shares of Hologic in the second quarter worth approximately $213,000. Finally, Cambridge Investment Research Advisors Inc. bought a new position in shares of Hologic in the second quarter worth approximately $213,000. Hedge funds and other institutional investors own 96.38% of the company’s stock.
Several brokerages have recently issued reports on HOLX. Zacks Investment Research cut shares of Hologic from a “hold” rating to a “sell” rating in a report on Tuesday. Jefferies Group LLC restated a “buy” rating and issued a $44.00 target price (down previously from $49.00) on shares of Hologic in a report on Tuesday, October 10th. Stifel Nicolaus restated a “buy” rating and issued a $45.00 target price (down previously from $48.00) on shares of Hologic in a report on Monday, October 9th. Needham & Company LLC restated a “buy” rating and issued a $50.00 target price on shares of Hologic in a report on Monday, October 2nd. Finally, Royal Bank Of Canada restated a “hold” rating and issued a $42.00 target price on shares of Hologic in a report on Friday, September 22nd. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and nine have given a buy rating to the stock. Hologic presently has a consensus rating of “Hold” and an average price target of $47.77.
In other news, Director Lawrence M. Levy sold 7,138 shares of the stock in a transaction on Monday, October 9th. The stock was sold at an average price of $37.38, for a total transaction of $266,818.44. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Lawrence M. Levy sold 9,596 shares of the stock in a transaction on Tuesday, October 10th. The stock was sold at an average price of $36.81, for a total value of $353,228.76. The disclosure for this sale can be found here. Insiders have sold a total of 30,775 shares of company stock worth $1,175,662 in the last three months. Corporate insiders own 0.79% of the company’s stock.
Shares of Hologic, Inc. (NASDAQ:HOLX) opened at 36.97 on Thursday. The stock’s 50 day moving average is $37.55 and its 200-day moving average is $41.76. The company has a market cap of $10.37 billion, a PE ratio of 13.77 and a beta of 0.91. Hologic, Inc. has a one year low of $35.15 and a one year high of $46.80.
Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Wednesday, August 2nd. The medical equipment provider reported $0.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.49 by $0.01. Hologic had a return on equity of 23.18% and a net margin of 25.65%. The business had revenue of $806.10 million for the quarter, compared to the consensus estimate of $799.70 million. During the same quarter in the prior year, the company earned $0.51 EPS. The business’s revenue was up 12.4% compared to the same quarter last year. Equities research analysts expect that Hologic, Inc. will post $2.01 earnings per share for the current year.
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.